Skip to main content

ADVERTISEMENT

Seth Wander, MD

Seth Wander, MD, PhD
Conference Coverage
01/04/2024
Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...
Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...
Seth Wander, MD, PhD, discussed...
01/04/2024
Oncology
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
12/12/2023
Cynthia Ma, MD, leads part 4 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for endocrine therapy for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 4 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for endocrine therapy for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 4 of...
12/12/2023
Oncology
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
12/12/2023
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of...
12/12/2023
Oncology
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
12/07/2023
Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 2 of...
12/07/2023
Oncology
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
11/30/2023
Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...
Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...
Cynthia Ma, MD, leads part 1 of...
11/30/2023
Oncology